obesity drug news today glp-1 september 22 2025 New Guidelines on Drugs for Released Outlook for obesity in 2025:
Description
[DOI] [PubMed] [Google Scholar] 41.Reid T
doi: 10.2174/157488910791213130 85 HolscherC
NOT recommended for treatment of type 1 diabetes or treatment of diabetic ketoacidosis Pharmacokinetics: oral administration, 65% bioavailability activity is terminated by conversion to inactive O-glucuronide metabolites (that are eliminated in the urine), with only minimal (~7%) metabolism by CYP3A4
View image online ( Glucagon-like peptide-1 (GLP-1) receptor agonists and GLP-1 receptor/glucose-dependent insulinotropic polypeptide (GIP) receptor dual agonists bind to their respective receptors on pancreatic beta cells to stimulate glucose-induced insulin secretion
She did not previously have any features of IIH, and she had brain imaging without stigmata of IIH
